-
Company Insights
Innovation and Patenting activity of HDC Holdings Co Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of HDC Holdings Co Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PEN-866 in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PEN-866 in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PEN-866 in Ovarian Cancer Drug Details: PEN-866 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PEN-866 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PEN-866 in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PEN-866 in Colorectal Cancer Drug Details: PEN-866 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PEN-866 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PEN-866 in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PEN-866 in Gastric Cancer Drug Details: PEN-866 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PEN-866 in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PEN-866 in Small-Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PEN-866 in Small-Cell Lung Cancer Drug Details: PEN-866 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PEN-866 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PEN-866 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PEN-866 in Pancreatic Ductal Adenocarcinoma Drug Details: PEN-866 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PEN-866 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PEN-866 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PEN-866 in Triple-Negative Breast Cancer (TNBC) Drug Details: PEN-866...
-
Product Insights
Wakeland HDC – The Quincy Apartments – California
Equip yourself with the essential tools needed to make informed and profitable decisions with our Wakeland HDC - The Quincy Apartments - California report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into the...
-
Product Insights
Wakeland HDC – The Quincy Senior Apartment Complex – California
Equip yourself with the essential tools needed to make informed and profitable decisions with our Wakeland HDC - The Quincy Senior Apartment Complex - California report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep...
-
Product Insights
HDC MidAtlantic/ Woodlawn Trustees – The Flats Housing Redevelopments – Delaware
Equip yourself with the essential tools needed to make informed and profitable decisions with our HDC MidAtlantic/ Woodlawn Trustees - The Flats Housing Redevelopments - Delaware report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...